
The weight-loss drug boom has become one of the internet’s biggest scams
More Videos
Published
8 months agoon
By
adminA production line of Wegovy injection pens for the Asian market at the Novo Nordisk A/S pharmaceutical manufacturing facility in Hillerod, Denmark, on Wednesday, Nov. 27, 2024.
Bloomberg | Bloomberg | Getty Images
One interpretation of the law of supply and demand is that when demand outstrips supply, scammers get busy. That’s certainly the case with the super-popular weight-loss drugs from Eli Lilly and Novo Nordisk.
As millions of Americans are prescribed injectable Ozempic and Mounjaro to treat type 2 diabetes, and Wegovy and Zepbound for obesity — and countless more without prescriptions seek them as “vanity drugs” to shed unwanted pounds — the manufacturers can’t keep up production. The GLP-1s, as they’re known, are pricey, too, and insurance often doesn’t cover them, provided consumers can find them.
That confluence of factors has laid the groundwork not only for a confusing online marketplace for compounded versions of the drugs — allowed by the Food and Drug Administration when proprietary ingredients are determined to be in short supply — but a proliferation of nefarious scams offering to sell both brand-name and counterfeit GLP-1s on websites and social media platforms.
Consumers have received Lilly- and Novo-branded GLP-1s from unauthorized sellers, counterfeit versions, completely different medications or nothing at all — other than an expensive rip-off. Most disturbing, Novo told CNBC that as of mid-November, it is aware of 14 deaths and 144 hospitalizations of people who had taken compounded semaglutide, the active pharmaceutical ingredient in Ozempic and Wegovy. It recently asked the FDA to ban the copycat drugs.
Within the past year, cybersecurity experts, consumer advocates, pharma researchers and media investigators have uncovered scores of accounts and content on TikTok, Facebook, Instagram and other social media platforms, as well as numerous websites, where bad actors have been doing business, much of it illegal or at least unethical.
In May, a joint investigation by the nonprofits Digital Citizens Alliance and Coalition for a Safer Web revealed how consumers are flocking to TikTok — which faces an uncertain future after a federal court on Friday upheld a law that would seek to ban the company in the U.S. on Jan. 19 — and other social media platforms and websites to purchase branded and illicit GLP-1s, often without a prescription. According to the report, scammers create accounts promising to sell the drugs for between $200 and $400 for a month’s supply — far below market prices — paid through Zelle, Venmo and PayPal rather than traditional credit cards so as to avoid tracking.
“Scammers take advantage of human emotion and human want, and the emotion and want now is that everybody wants to lose weight,” said Eric Feinberg, vice president of content moderation for the Coalition for a Safer Web. “It’s a perfect audience to use online to take advantage of people psychologically and emotionally.”
A common ruse the investigation exposed was sellers saying the drugs were coming from overseas and then claiming that the order was held up in customs, requiring an additional $300 to $500 payment to release it. The scammers were devious, said Tom Galvin, executive director of Digital Citizens Alliance. “They send a tracking number from a delivery service that shows you where your package is, but the tracking number is BS.” Digital Citizens shelled out just over $3,000 to purchase GLP-1s, and yet the money yielded no deliveries of the drugs.
No-delivery ploys can exact a serious financial toll on victims, but “the more scary ones are where you do get a product and don’t even know whether you can trust [it] or if it’s a valid company,” said Abhishek Karnik, director for threat research and response for cybersecurity firm McAfee.
Phishing for weight-loss drug victims
Tracking activity over the first four months of this year, McAfee’s Threat Research Team uncovered just how prolific weight-loss scams have become across malicious websites, scam emails and texts, posts on social media and online marketplace listings. From January through April, McAfee researchers discovered 449 risky website URLs and 176,871 dangerous phishing attempts centered around Ozempic, Wegovy and semaglutide, an increase of 183% compared to October through December 2023.
Karnik’s team has continued to monitor these criminal activities. “We’ve identified [a total of] 367,000-plus phishing attempts, and between May and August, the number of [risky] URLs we found increased by 135%,” he said.
JAMA Network Open in August published the results of a study by an international group of researchers who searched the global internet to ferret out websites for online pharmacies advertising semaglutide for sale. Among the 317 operations found, more than 42% were illegal, operating without a valid license, selling medications without prescriptions and shipping unregistered and falsified products. Six purchases were made, but only three were delivered.
A recent CNBC investigation explored the murky international world of counterfeit weight-loss drugs. Among its findings, investigators recounted the seizure in the UK last year of hundreds of what appeared to be Ozempic pens, but were in fact insulin pens relabeled as Ozempic. They also discovered from Lilly that its retatrutide, a novel GLP-1 drug still in clinical trials and not FDA-approved, was being marketed to the public.

Counterfeits and diverted drugs — branded GLP-1s sold on the black market — originate from many countries, including India, China, the UK, Mexico and Turkey. One of the destinations where they make their way to the U.S. was New York’s JFK International Airport. According to the U.S. Customs and Border Protection, since January 1, the agency had made more than 198 seizures of products labeled as Ozempic.
In response to this glut of fraudulent activity, social media companies and web operators have employed human monitors and machine technology to identify and shut down online scammers. A TikTok spokesperson, without detailing its various monitoring efforts, referred to the company’s community guidelines. “We strictly prohibit the trade of drugs, and we do not allow attempts to defraud or scam members of our community,” the spokesperson said. “Our advertising policies also prohibit the advertising of weight-loss products, including weight-loss injections and fat-burning pills.”
Despite official policies, however, undeterred violators find workarounds when their accounts are shuttered. They might set up another account with the drug names misspelled, spaces between letters or mash-ups of semaglutide and terzepitide. Many instruct interested buyers to direct message them or send links to Telegram and other dark websites that encrypt content and provide anonymity.
“The social media platforms are the new street corners for drug dealers, and they move from place to place,” Galvin said. “It’s a game of whack-a-mole.”
Bags of counterfeit Novo Nordisk A/S Ozempic and Wegovy, foreground, and other fake drugs at a warehouse operated by the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) in London, UK, on Monday, Feb. 27, 2024. The UK task force tracks down illegal websites, monitors social media and even carries out raids to stamp out sales of fake “skinny jabs” as both organized crime and unscrupulous lone entrepreneurs look to capitalize on the weight-loss frenzy.
Bloomberg | Bloomberg | Getty Images
For this article, CNBC found more than a dozen TikTok accounts that appeared to be selling GLP-1s in violation of its policies, including @ozempic_weightloss, @sema.irel and @semaglutideandtr. Soon after relaying the information to TikTok, we were told that all had been removed, except one, which was not in violation.
The widespread compounding of GLP-1s is another contributor to the dodgy marketplace for the drugs. In April and December of 2022, respectively, the FDA determined that semaglutide and tirzepatide were in short supply, opening the floodgates for compounding pharmacies and outsourcing facilities to manufacture, distribute and market copies, typically sold through telehealth companies, medical spas and wellness centers.
Compounded GLP-1s, unlike Lilly’s and Novo’s brands, are not FDA-approved, which means they do not undergo the agency’s review for safety, effectiveness and quality before they’re marketed. Instead, the FDA and state boards of pharmacy register, license and inspect compounding facilities and ingredients. And while some compounders meet regulatory requirements, such as Henry Meds, Noom Med, Ro and Hims & Hers Health, many others don’t.
Publicly traded Hims & Hers launched its gender-focused telehealth platform in 2017, adding compounded semaglutide to its weight-loss program this past May. “We waited until we were able to find the right compounding partner,” said Dr. Patrick Carroll, the company’s chief medial officer. Besides that partner, BPI Labs, Hims & Hers acquired another, MetasourceRx, in September. The company also sells branded Ozempic and next year will offer liraglutide, the first generic GLP-1.
FDA scrutiny
In the meantime, the FDA is investigating the bad actors in the compounding world. “Purchasing prescription drugs from unregulated, unlicensed sources without a prescription is risky,” a spokesperson for the agency told CNBC. “We urge consumers to be vigilant and to utilize tips tools from the FDA’s BeSafeRx campaign to help them safely buy drugs online.”
In May, the KFF Health Tracking Poll found that about one in eight adults (12%) said they had taken a GLP-1 drug, with about half, or 21 million, actively using the medications. Nearly 80% purchased the drugs or a prescription for them — at a cost between $936 to $1,349 per month before insurance coverage, rebates or coupons — from a primary care doctor or a specialist, according to the survey. Fewer reported getting them from an online provider or website (11%), a medical spa or aesthetic medical center (10%), or from somewhere else (2%). But that doesn’t count the inestimable number of individuals who have obtained GLP-1s without prescriptions through unregulated online channels and illicit online compounding pharmacies, many operating overseas.
While social media companies police illegal sellers of GLP-1s, hundreds of influencers are touting the drugs and their journeys using them across the platforms with impunity, according to a Fast Company report. Many influencers are recruited and paid by telehealth companies.
Meanwhile, household names have been increasingly speaking out about their personal use of these drugs, which increases familiarity and curiosity among the public. In October, People profiled 64 celebrities — including Kathy Bates, Elon Musk, Oprah Winfrey, Andy Cohen, Billie Jean King and Rob Lowe — who have talked about their weight-loss drug experiences, mostly on social media.
Currently, Lilly’s and Novo’s GLP-1s are prescribed only for type 2 diabetes and obesity. But as researchers find additional conditions that can be treated with the drugs — including cardiovascular disease, kidney disease, dementia and addiction, and most recently even knee pain — prescriptions will increase exponentially.
In September, an article in the Annals of Pharmacotherapy warned against manufacturers that use a legal loophole to sell vials containing semaglutide and tirzepatide to consumers without a prescription by stating that the drugs are for “research purposes only” and/or “not for human consumption.” The authors conducted an internet search for such scofflaws, uncovering 40 websites selling what were labeled as “peptides” to consumers.
The FDA has sent warning letters to a handful, including Miami-based US Chem Labs in February, citing several violations and requesting action within 15 days. As of Dec. 6, CNBC found that the company still listed compounded semaglutide as available on its website. US Chem Labs could not be reached by phone and an email request for comment was not returned by press time.
The authors of the Annals of Pharmacotherapy article also identified three companies that were advertising GLP-1s on Facebook, owned by Meta. “Our policies prohibit content that defrauds people by promoting false or misleading health claims, including those related to weight loss, and we remove this kind of content when we become aware of it,” a Meta spokesperson told CNBC. CNBC subsequently sent Meta the names of the three companies, and several days later their Facebook pages were removed.
Eli Lilly, Novo Nordisk battle with copycat drugs
Workers walk past manufacturing equipment at Eli Lilly & Co. manufacturing plant in Kinsale, Ireland, on Sept. 12, 2024. Lilly has been bulking up its production capacity since 2020, investing more than $17 billion into developing new plants and expanding existing facilities for the weight-loss and diabetes drugs that are expected to become some of the best-selling medicines of all time.
Bloomberg | Bloomberg | Getty Images
Lilly and Novo are in a quandary regarding compounders. The copycats have filled a void while the branded GLP-1s are in shortage, attracting patients who can’t access or afford them.
But now the manufacturers want their domains to themselves. Lilly has sent cease-and-desist letters to numerous compounding sellers, and both companies have filed lawsuits against numerous compounding pharmacies, alleging trademark infringement and deceptive marketing.
On October 2, the FDA declared that Lilly’s tirzepatide was no longer in short supply, ostensibly putting compounders of that ingredient out of business. Two weeks later, though, after a public outcry from compounders’ patients and a federal lawsuit brought by compounding pharmacies, the FDA backtracked, saying it would reevaluate whether the drug is available and make a decision in mid-November.
Yet, on November 22, the FDA said it was still assessing the situation and agreed to not take action against compounders of tirzepatide until December 19, unless the agency makes an earlier decision.
Novo’s semaglutide is still listed as “currently in shortage” by the FDA, although the agency also lists Ozempic and Wegovy as “available.” A Novo Nordisk spokesperson told CNBC, “It’s important to note that availability doesn’t always mean immediate accessibility at every pharmacy. Patients may experience variability at specific locations, regardless of whether a drug is in shortage.”
Lilly and Novo have advocated for broadening insurance coverage for the drugs, and the Biden administration recently proposed that Medicare and Medicaid extend their coverage for obesity medications. Although that plan could be scuttled by the incoming Trump administration. Robert F. Kennedy, Jr., Trump’s nominee to head the Department of Health and Human Services, has suggested that obesity should be tackled through healthy eating, not drugs.
The obesity drug market volatility has shown up in recent earnings. In its third-quarter report on October 30, Lilly fell short of profit and revenue expectations, partly due to disappointing sales of its GLP-1s, even as demand for them continued to soar. A week later, Novo reported third-quarter earnings in line with expectations, strengthened by robust sales of Ozempic and Wegovy. Nonetheless, the Danish company narrowed its 2024 full-year growth guidance, reflecting, according to a statement from the company, “expected continued periodic supply constraints and related drug shortage notifications.”
Both pharma giants continue to invest billions to increase production facilities and capacity. This week, Lilly said it was investing $3 billion to increase obesity drug production at a Wisconsin plant.
Regardless, demand for GLP-1s — no matter if they’re branded, compounded or counterfeit or where they’re purchased from — is certain to keep growing. That will put more pressure on social media platforms and web operators to guard against scams.
Galvin suggested that the companies need to work together to identify scammers as they navigate between platforms to avoid detection. “Too many platforms look at this as a PR problem and not an internet safety problem,” he said. “If they were collaborating with each other to identify the bad actors and shared that information, people would find a lot less of them.”
You may like
Technology
Trump warned by top Senate Democrats to rethink advanced AI chip sales to China
Published
2 days agoon
August 16, 2025By
admin
Nvidia CEO Jensen Huang, right, speaks alongside President Donald Trump about investing in America, at the White House in Washington, on April 30, 2025.
Jim Watson | AFP | Getty Images
Six Senate Democrats on Friday released an open letter asking President Donald Trump to reconsider his decision to allow tech giants Nvidia and Advanced Micro Devices to sell AI semiconductor chips to China in exchange for 15% of revenue from the sales.
The letter — signed by Senators Chuck Schumer, D-N.Y.; Mark Warner, D-Va.; Jack Reed, D-R.I.; Jeanne Shaheen, D-N.H.; Christopher Coons, D-Del.; and Elizabeth Warren, D-Mass. — was in response to an Aug. 11 announcement by Trump that Nvidia and AMD would pay the U.S. government a 15% cut of revenue from chip sales to China in exchange for export licenses.
“Our national security and military readiness relies upon American innovators inventing and producing the best technology in the world, and in maintaining that qualitative advantage in sensitive domains. The United States has historically been successful in maintaining and building that advantage because of, in part, our ability to deny adversaries access to those technologies,” the letter states.
“The willingness displayed in this arrangement to ‘negotiate’ away America’s competitive edge that is key to our national security in exchange for what is, in effect, a commission on a sale of AI-enabling technology to our main global competitor, is cause for serious alarm,” the letter continues.
Senators also warned that selling advanced AI chips — specifically Nvidia’s H20 and AMD’s MI308 chips — to China could help strengthen its military systems, a claim that Nvidia denies.
In a statement to CNBC, a Nvidia spokesperson said: “The H20 would not enhance anyone’s military capabilities, but would have helped America attract the support of developers worldwide and win the AI race. Banning the H20 cost American taxpayers billions of dollars, without any benefit.”

The letter from Senate Democrats also requests a detailed response from the administration by Friday, Aug. 22, regarding the current deal involving Nvidia and AMD, as well as any similar arrangements being made with other companies.
“We again urge your administration to quickly reverse course and abandon this reckless plan to trade away U.S. technology leadership,” the letter states.
A request for comment from the White House and AMD was not immediately returned.
Despite Trump allowing chip sales to resume, it has already become clear that China isn’t welcoming Nvidia back with open arms, instead urging tech companies to avoid buying U.S. companies’ chips, according to a Bloomberg report.
“We’re hearing that this is a hard mandate, and that [authorities are actually] stopping additional orders of H20s for some companies,” Qingyuan Lin, a senior analyst covering China semiconductors at Bernstein, told CNBC.
In a separate report, The Information said regulators in China have ordered major tech companies, including ByteDance, Alibaba, and Tencent, to suspend Nvidia chip purchases until a national security review is complete.
— CNBC’s Kristina Partsinevelos contributed to this report
Technology
Bill Gates meets Willy Wonka: How Epic’s 82-year-old billionaire CEO, Judy Faulkner, built her software factory
Published
2 days agoon
August 16, 2025By
admin
Judy Faulkner, founder and chief executive officer of Epic Systems Corp., during the Forbes Healthcare Summit in New York, Dec. 5, 2023.
Michael Nagle | Bloomberg | Getty Images
Do not go public. Do not acquire or be acquired. Software must work.
These are the first three of the 10 commandments splashed across bathrooms and breakrooms at Epic Systems’ sprawling 1,670-acre campus in Verona, Wisconsin, just southwest of Madison.
It’s not the wackiest part of working at the health-care software giant. Once a month, most of the company’s 14,000 employees pack into an underground auditorium called Deep Space for a mandatory staff meeting, which some jokingly refer to as “work church.” Executives go over company news and objectives. They also lead a grammar lesson, such as whether it’s OK to end sentences with a preposition and when to use “who” or “whom.”
Epic’s CEO is 82-year-old Judy Faulkner, who started the company in a Wisconsin basement in 1979 and has helmed the enterprise ever since. En route to building a business with $5.7 billion in annual revenue, Faulkner has kept significant distance from her tech peers, both physically and otherwise. Epic is about 2,000 miles east of both Seattle and Silicon Valley, and the company has never taken money from venture capitalists.
“I’ve described her as a female cross between Bill Gates and Willy Wonka,” Dr. Eric Dickson, CEO of UMass Memorial Health, said in an interview. The hospital system is an Epic customer, Dickson said, adding that he’s known Faulkner for around 20 years.
While Wonka is, of course, a fictional character, Gates for many years was the world’s wealthiest person, thanks to his enormous stake in Microsoft, before donating his way to 14th on the Forbes billionaires list. At the top of the leaderboard is Tesla’s Elon Musk, followed by Oracle’s Larry Ellison, Meta’s Mark Zuckerberg and Amazon’s Jeff Bezos.
Faulkner ranks 430th, with an estimated net worth of $7.8 billion, based on what Forbes says is her 43% ownership of Epic. The publication lists Epic as among the five largest private U.S. tech software and services companies by revenue.
Epic is best known for its dominance in electronic health record, or EHR, software. An EHR is a digital version of a patient’s medical history that’s updated by doctors and nurses. About 42% of acute care hospitals in the U.S. use Epic, putting it way ahead of Oracle Health, which is in second place at 23%, according to an April report from Klas Research. Oracle acquired its way into the market with the $28 billion purchase of Cerner, a deal that closed in 2022.
Epic says its technology is used in 3,300 hospitals and 71,000 clinics and by 325 million patients worldwide. Starting Monday, thousands of health-care executives will descend on Epic’s corporate headquarters for the company’s Users Group Meeting, one of its largest annual on-campus events.
As ubiquitous as Epic’s technology is across much of the health-care sector, doctors, hospital administrators, startups and patients have their share of complaints about the software’s user experience and its interoperability, or ability to work with other tools.
“With half a million or so clinicians using Epic, there will be some who find it easy and some who find it difficult,” an Epic spokesperson said in a statement.
Some folks might question Epic’s commitment to its third commandment, but there’s no doubting the company’s allegiance to the first one.
From Epic’s early days, Faulkner has been averse to the idea of running a public company and what she’s called the “tyranny of the quarter.” She said she came to that view after researching public companies and reading shareholder comments.
“They were vitriolic, in many cases, because the only thing they were looking at was return on their investment,” Faulkner told CNBC. “Sometimes, there’s a lot more than that.”
Without the benefit of public stock, Faulkner’s wealth doesn’t multiply at the same rate as that of her fellow tech founders and CEOs. She’s fine with that.
Faulkner, who rarely grants interviews, agreed to sit down for a half-hour chat with CNBC at Epic’s headquarters, where office buildings are themed, with many inspired by fiction, including “The Wizard of Oz,” “Alice in Wonderland” and the Harry Potter stories.
The interview took place in the Andromeda building in a conference room called The Cottage, which is connected to her office. Two of the walls are plastered with quotes such as “The geek shall inherit the Earth” and “All lasting business is built on friendship.” Faulkner’s dog Tundra, a fluffy Samoyed, also made an appearance.
‘The Trust Protector Committee’
A sign on the Epic campus says “Epic Intergalactic Headquarters.”
Courtesy: Epic
Faulkner celebrated her 82nd birthday Monday. While she has yet to publicly disclose when she plans to step down from her role, Faulkner confirmed that she has a succession plan in place that ensures Epic will remain privately held and constructed firmly as she envisioned long after she’s gone.
Faulkner has never sold any of her voting shares, and that stock will be transferred into a trust after her death, according to Faulkner and Epic. The plan for now is that the trust will be governed by a voting committee made up of Faulkner’s husband, Dr. Gordon Faulkner, a retired pediatrician; her three children, and five longtime Epic employees, though Faulkner said she might include some additional staffers to make sure enough voices are represented.
Members of the committee can’t vote for the company to go public or be acquired, among other rules, as she has previously disclosed. Some of the provisions are less consequential, such as a recommendation that the trust’s telephone hold music should be classical.
“I like classical music,” she said. “I think when I was a child that it was played in our house a lot, just on the radio, just on the record player.”
For further safekeeping, Faulkner established an oversight board called “The Trust Protector Committee,” Epic said, consisting of three health-care leaders — all Epic users. Its job is to sue members of the trust’s voting committee if they don’t follow the rules.
The names of members of the voting committee and oversight board won’t be released, Faulkner told CNBC, but she said she’s identified who she would like to participate.
After running Epic for the past 46 years, Faulkner has amassed her fair share of admirers and critics, with some in the latter camp even taking Epic to court.
But Faulkner continues to flout conventional business practices and has built Epic, despite its flaws and complexities, into the most powerful technology company in U.S. health care.
Reflecting on her approach to leadership and decision-making, Faulkner said, “Just have the guts to do what you know is the right thing to do.”
CNBC spoke with two dozen Epic customers, former Epic employees, industry experts and people close to Faulkner for this article, some of whom asked not to be named in order to speak freely. Details about Faulkner’s personal, educational and professional history were obtained from Faulkner directly, her Epic website testimonials, Epic, obituaries, news reports and publicly available records.
Sometimes when I do something that’s tough, I think of my mother, who went to jail in her 80s for protesting at a nuclear arms site, and I think, ‘I’m my mother’s daughter.’
Judy Faulkner
CEO of Epic
Faulkner and her two siblings grew up in Erlton, New Jersey, now a part of Cherry Hill. Her father, Louis Greenfield, was an independent pharmacist who ran his own store, complete with a soda fountain. Her mother, Del Greenfield, was a peace activist who was involved with the South Jersey Peace Center and the Oregon Physicians for Social Responsibility, which shared in the 1985 Nobel Peace Prize for its work in preventing nuclear war.
“Sometimes when I do something that’s tough, I think of my mother, who went to jail in her 80s for protesting at a nuclear arms site, and I think, ‘I’m my mother’s daughter,'” Faulkner said.
Faulkner’s parents, who both died in 2007, are honored at Epic’s campus. Employees can get ice cream at Lou’s Soda Fountain, while Del’s Nobel Prize certificate hangs in the hallway across from The Cottage.
Faulkner discovered a love of math as a seventh grader, when her teacher would leave puzzles on the blackboard each day, she said in one of her testimonials, the short stories and anecdotes she shares once a month on Epic’s website. She earned her undergraduate degree in math from Dickinson College in 1965.
After learning how to program during a summer job, Faulkner then enrolled in the University of Wisconsin–Madison’s nascent computer science program and was in graduate school there until 1970.
At UW–Madison, Faulkner took a course about computing in medicine that was taught by a pioneering physician, Dr. Warner Slack, one of the first people to recognize the promise of the technology within health care.
Faulkner began working with Slack and his team, and she was tasked with developing a system that could keep track of patient information over time. She eventually built what would become the kernel for Epic, though it took years of urging from potential users before she would actually launch the company in 1979. In the interim, she taught college-level computer science.
When Faulkner finally opened Epic for business, she did so with a small amount of cash from some colleagues at an initial valuation of $70,000. Now the company is worth many billions of dollars, though estimates of its valuation differ.
Some of the original shareholders eventually sold their stock back to the company.
“They got very good returns,” Faulkner wrote in a testimonial.
An accidental entrepreneur
Epic’s Deep Space Auditorium.
Epic Systems
Faulkner has publicly described herself as “the accidental CEO.”
She told CNBC she read books and took daylong or multiday courses to learn more about management, business and leadership. But she didn’t always follow their advice.
“I never got an MBA, which I think is a really good thing,” Faulkner said. “They would have taught me, ‘Here’s how you do venture capital.’ We didn’t do it. ‘Here’s how you go public.’ We didn’t do it. ‘Here’s how you do budgets.’ We don’t have budgets. We say, if you need it, buy it. If you don’t need it, don’t buy it.”
At the company’s Users Group Meeting last year, Faulkner took the stage dressed as a swan, with a plume of feathers in her hair. Every UGM meeting has a theme — this one was “storytime.” In costume, Faulkner told the thousands of health-care executives in attendance about her aversion to the public market.
“Why be owned by people whose interest is primarily return of equity?” she said.
She’s equally opposed to selling the business, which she makes clear in the company’s second commandment.
That hasn’t stopped other executives from trying to change her mind.
In 2017, at the Digital Healthcare Innovation Summit in Boston, former General Electric CEO Jeff Immelt revealed that he’d spoken with Faulkner about acquiring Epic.
Faulkner shut him down immediately.
“It was a five-minute meeting — perhaps the shortest in history,” Immelt said, according to a report from Healthcare IT News. The report said he’d also considered buying Cerner.
Faulkner confirmed the encounter with CNBC.
“Others have asked to come and persuade us, and I’ve heard our staff say to them, ‘Just leave your car running,'” she said.
Faulkner has said in testimonials that she’s avoided buyers in order to remain independent and preserve Epic’s unique culture, and she doesn’t make acquisitions, calling them a distraction.
But no matter how much she loves her company and her job, at some point, somebody else is going to have to run Epic.
Faulkner has remained mum about who will be her eventual successor, other than to say that the person will have to be a software developer and a longtime Epic employee.
The obvious choice, according to 10 former Epic employees who spoke with CNBC, is Sumit Rana, who was named president of the company last August. The 49-year-old joined Epic right out of college in 1998 and helped build the company’s patient portal called MyChart.
Rana, who was a toddler when Faulkner founded Epic, has been participating in more high-profile speaking engagements of late, including representing the company during the opening panel at the Centers for Medicare & Medicaid Services’ Quality Conference in July.
Faulkner declined to say whether Rana is the top contender for the job.
“That’s the company’s business,” she said. “Sumit is a wonderful employee, and he would make a good CEO, but we’re not publicly announcing anything.”
A building on Epic’s Farm Campus.
Courtesy: Epic
While Faulkner doesn’t say much about the company’s succession plans, she hasn’t been shy about her plans for her personal wealth.
In 2015, she signed The Giving Pledge and agreed to donate 99% of her assets to charity, a decision that was inspired in part by a dinner she had with Berkshire Hathaway CEO Warren Buffett that year.
Buffett created The Giving Pledge with Bill Gates and Gates’ then wife, Melinda French Gates, in 2010, encouraging the world’s richest people to give away the majority of their wealth.
Following Faulkner’s pledge, she launched a family foundation called Roots & Wings with her husband in 2020. Roots & Wings provides grants to nonprofits that support low-income children and families. Faulkner’s daughter, Shana Dall’Osto, serves as executive director of the organization.
Faulkner has been selling her nonvoting shares back to the company, giving the proceeds directly to Roots & Wings.
“I’ve never cashed a single share for myself,” Faulkner told CNBC.
‘Bet the ranch’
Installing an EHR is an extremely complicated and costly project for health systems. If it doesn’t go well, it could “blow up” the whole business, Dr. Robert Grossman, CEO of NYU Langone Health, told CNBC in an interview.
“We bet the ranch on Epic, let’s be very honest,” he said.
Fans of Epic say the company is fully tuned in to its customers’ needs.
“They don’t just operate and dial in,” said Michael Mayo, CEO of Baptist Health in northeast Florida. “They visit our campus. They’re immersed here. They know our teams across our IT [information technology] component and our caregivers. They are in our facilities. And when we went live, which is a pretty scary time, they were in full force here.”
Each health system that uses Epic has a point person called a “BFF,” or “best friend forever,” who is available to answer questions and help solve problems. Epic doesn’t outsource any incoming calls to third parties, the company says, so staff members are responsible for picking up the phone 24/7.
Faulkner also makes herself easily accessible to customers, executives said.
Mike Slubowski, CEO of Trinity Health, which operates 93 hospitals across 26 states, said Faulkner always answers his emails within the day, if not the hour.
She holds recurring meetings with senior health-care executives by phone or video call to answer questions and talk through an organization’s specific needs and ideas. Executives told CNBC that Faulkner takes copious notes and is receptive to feedback. If she doesn’t have an answer, she promptly calls someone who does.
“She’ll stop right there and say, ‘Get so-and-so on the phone,'” said Dickson, of UMass Memorial Health. “I don’t know what so-and-so was doing prior to getting the call, but it’s clear that when Judy calls, you drop what you’re doing.”
Pete Durlach, corporate vice president for health and life sciences at Microsoft, said he’s been in meetings with Epic staffers who have gotten these impromptu calls. Microsoft and Epic have been close partners for around two decades, a relationship that’s gotten tighter as cloud and artificial intelligence technologies have advanced, he said.
Epic employees at work.
Courtesy of Epic
“People definitely answer the phone when Judy calls,” Durlach said.
Epic doesn’t advertise or have a traditional marketing department; the company has relied heavily on word of mouth. Faulkner has also proven to be an effective salesperson.
Ardent Health CEO Marty Bonick said that when he was debating whether to convert some of his hospitals to using Epic products, Faulkner ultimately helped sway him.
Ardent Health owns 30 hospitals and 280 outpatient care sites across six states. When Bonick joined Ardent in 2020, he said, roughly two-thirds of Ardent’s hospitals were using Epic. Bonick said he’d never worked with Epic and wanted to make sure that switching over the remainder of Ardent’s hospitals would be worthwhile.
Bonick said he told Faulkner that he’d heard Epic’s product was expensive and difficult to implement.
“She came back with a presentation that she delivered personally, and spent probably over 90 minutes,” said Bonick, who was ultimately sold on the conversion. “I had to say, ‘OK, time out. I’ve got another meeting to go to,’ but she really was not watching the clock.”
Graveyard of competitors
Epic is used by all 20 of the top hospitals from the U.S. News & World Report rankings, and by the country’s seven largest health plans, according to the company.
Its dominance has come with plenty of controversy.
Epic faces accusations of anticompetitive practices in two lawsuits from the past year. One was filed in September by data startup Particle Health, which alleges that Epic has used its EHR market power to “snuff out” competition in other emerging health-care markets.
Epic said in response it would “vigorously defend itself against Particle’s meritless claims.”
The second lawsuit was filed in May by CureIS Healthcare, a managed care services company that claims Epic has engaged in a “multi-prong scheme to destroy” CureIS’ business. CureIS alleges Epic has interfered with its customer relationships, blocked access to necessary data and raised unfounded security concerns, according to a complaint.
An Epic spokesperson told CNBC at the time of the filing that the company “believes in free and fair competition, and we also believe our customers are in the best position to choose the right solutions to meet their needs — whether with Epic or by adopting other products and services.”
Epic’s competitors have also long accused the company of being territorial over its data and impeding efforts to share patient information between vendors.
In a blog post last year, Oracle Executive Vice President Ken Glueck wrote that “everyone in the industry understands that Epic’s CEO Judy Faulkner is the single biggest obstacle to EHR interoperability.”
Interoperability, in this case, refers to the exchange of electronic health data from one health-care organization to another. Since health data is siloed, stored across dozens of formats and protected by federal laws such as the Health Insurance Portability and Accountability Act, or HIPAA, it’s a complex undertaking.
Over the years, startups such as Practice Fusion and DrChrono have tried to crack the EHR market with promises of greater openness and more user-friendly products, but they have never become more than niche offerings. Some failed completely.
Epic promotes its own interoperability tools such as Care Everywhere and EpicCare Link, which allows customers and their affiliates to exchange data with one another. Epic also participates in larger data exchange networks.
The Oz office building on Epic’s campus.
Courtesy: Epic Systems
Attention to detail
One of Epic’s biggest feats in its 46 years is managing to attract high-level tech talent far away from the nation’s engineering and business hubs, especially given the harsh Midwestern winters in Wisconsin.
That’s where Epic’s headquarters comes into play. It’s a campus that industry executives and former employees likened to a techie’s Disney World.
All 28 office buildings are themed. They’re clustered into mini-campuses, with names such as Prairie Campus, Wizards Academy Campus and Storybook Campus.
The offices are designed by architecture firm Cuningham, which has also worked on projects at Disney theme parks all over the world. John Cuningham, the founder of the firm, said he’s worked with Faulkner for 30 years, and that she’s always been very involved in the process.
Epic’s first campus, for instance, has more than 80 bathrooms, and Faulkner wanted to know the details of all of them.
“Each one,” he said. “Light fixtures, faucets, mirrors, wallpaper, tile, sinks. I mean, I was thinking, ‘Oh, she’ll last for 10.’ She did all 85, and she still does that,” he said.
I went down the slide, like everybody.
Warner Thomas
CEO of Sutter Health
On Epic’s grounds, a metal wizard stands in the courtyard of a castle, giant chocolate chips mark the entryway to a faux chocolate factory, and a hanging bridge leads to the company’s very own treehouse.
Inside a building inspired by “Alice in Wonderland,” there’s a slide that takes employees into a small room where everything is upside down. It’s popular with visitors.
“I was kind of blown away,” Warner Thomas, CEO of Sutter Health, a nonprofit health system in Northern California, told CNBC about his first trip to Epic’s campus. “I went down the slide, like everybody.”
The buildings are brimming with trinkets, ceramics, mosaics and paintings that Epic employees get to help source. Faulkner recruits a small group of volunteers to go with her to local art fairs and buy decorations for the campus. Some pieces cost thousands of dollars, according to former employees.
Faulkner said she had just returned from an art fair ahead of her interview with CNBC.
‘Everybody knows Judy’
A cow-print bike on Epic’s campus.
Courtesy: Epic
Despite the fantastical themes on-site, employees are tasked with very real responsibilities. Since Faulkner places such a strong emphasis on supporting her customers, she holds her staff to high standards.
Most employees work in person five days a week. Hours can be long and burnout is common, former employees say. In June, The Economist analyzed 900 companies across 19 industries, and found that Epic had the worst work-life balance in the software and IT services category. Several former employees told CNBC their work at Epic was all-consuming.
Epic said the average employee works between 44 and 45 hours a week, based on monthly time sheet submissions between June 2024 and June 2025. The company said its turnover rate last year was 7%.
“People at Epic are dedicated and work hard,” an Epic spokesperson said in a statement.
Epic workers are entrusted with big projects, expected to interact directly with customers and generally take on a lot of responsibility. For some employees, that includes working alongside hospitals as they implement Epic’s technology.
“Some of these implementations really sucked,” said Brendan Keeler, a former Epic employee who frequently blogs about the company online. “So much of the success of an implementation was just a function of the politics of the hospital.”
Epic recruits the vast majority of its employees straight out of college, so its staff is relatively young. All new staffers go through extensive training, including a five-hour corporate philosophy class where they’re taught how to be a successful employee.
Faulkner said she used to teach the class by herself but that she now has help from one or two other people.
Faulkner’s influence is present in every corner of Epic’s campus, in its product and across much of the health-care industry.
“Everybody knows Judy Faulkner,” said Thomas, of Sutter Health.
She’s still got a lot to do. The health-care industry is reckoning with rising costs, staffing shortages, the impact of AI and the Trump administration’s hefty cuts in the areas of medical science and research.
And Faulkner isn’t ready to quit.
“It’s interesting and it’s challenging and it’s worthwhile,” Faulkner said.

Technology
Samsung taking market share from Apple in U.S. as foldable phones gain momentum
Published
2 days agoon
August 16, 2025By
admin
In 2014, Apple and Samsung were duking it out to rule the U.S. smartphone market. Samsung was selling devices with large screens, and iPhone fans were demanding a response.
It took Apple some time, but the company finally released the iPhone 6, breaking with previous iterations and giving consumers a large-screen option. The iPhone won.
But more than a decade later, recent smartphone sales and shipment figures signal that the Apple-Samsung fight has returned. And once again, it’s all about the screen.
In the second quarter, shipments from Samsung surged in the U.S., with its market share rising from 23% to 31% from the prior period, according to data from Canalys. Apple’s market share during the quarter declined to 49% from 56%.
Apple remains on top of the U.S. smartphone market, taking the majority of new smartphone sales in the U.S. It’s often in second place around the world, but the recent slips points to turbulence for Apple for the first time in well over a decade.
That’s one reason investors have sent Apple shares down 7.5% this year, underperforming all of the U.S. megacap tech companies other than Tesla. Samsung’s stock, meanwhile, is up about 35% in 2025.
In July, Samsung introduced a pair of innovative new phones that feature foldable screens. One model, the Z Fold 7, can effectively turn into a tablet, while the Z Flip resembles an old-school flip phone with modern smartphone features. They were added to Samsung’s catalog of phones released this spring under its Galaxy brand, including a thin-and-light phone called the Galaxy S25 Edge.
The devices are also getting a lot of traction on social media, particularly around durability tests.
One user posted a livestream that showed him bending the Z Fold 7 over 200,000 times in a row. The video has been clipped and shared widely on social media, with one version of the clip accumulating more than 15 million views on YouTube.
In the past month, Samsung’s premium devices, including the Z Fold 7, were mentioned over 50,000 times on social media, and 83% of those mentions were positive or neutral, according to data from Sprout Social, a social media analytics company.
The market share numbers aren’t just the result of user preferences. Much of the shift in shipment figures in the June quarter, analysts said, can be attributed to tariffs, which are causing “disruption” in the industry as smartphone makers use different strategies to minimize the impact on their business.
But Samsung’s gains also reflect the company’s ability to offer a much wider range of products at different prices compared to Apple. That includes low-end phones, which accounted for much of Samsung’s second-quarter U.S. improvement, as well as high-end devices that cost more than any individual iPhone.
Samsung’s Galaxy and Z phone lineup “stretches from $650 up to $2,400. That is a massive span of devices,” said Canalys analyst Runar Bjorhovde. “There is an idea that you can target people at every single price point, and you can meet them at every spot.”
The iPhone has pretty much looked the same since 2017 — a rectangular piece of glass with a touchscreen on the front, and a few cameras on the back. These days, the company offers a series of four slates ranging from $829 to $1,599. Samsung and others are starting to go beyond the so-called candy bar shape and experimenting with new form factors.
Apple is expected to start doing the same — beginning with a potential launch next month of a slimmer iPhone that will compete with Samsung’s Galaxy Edge.
“Apple is clearly betting that its 5.5mm Air model is going to lift its fortunes as testing suggests a strong desire for the new form factor,” wrote Loop Capital managing director John Donovan in May.
JPMorgan Chase analyst Samik Chatterjee wrote in a report last month that Apple may release a folding phone next year to compete with Samsung’s Z Fold.
“Investor focus has already turned to the 2026 fall launches with Apple expected to launch its first foldable iPhone as part of the iPhone 18 lineup in September 2026,” Chatterjee wrote.
Trying new form factors offers Apple the opportunity to sell devices at higher prices, according to Bjorhovde.
Apple’s most expensive phone, the iPhone 16 Pro Max, currently starts at $1,199 for 256GB of storage and can go up to $1,599 for a version with 1TB of storage. The Samsung Galaxy Z Fold 7, which was announced last week, starts at $1,999 for the 256GB version and tops out at $2,419 for the 1TB version.
Chatterjee said he thinks Apple’s version of a folding phone could start at $1,999. Apple declined to comment.
A person holds a Samsung Galaxy Z Fold 7 phone during an event in New York, U.S., July 8, 2025.
Jeenah Moon | Reuters
Folding phones finally mature
Samsung’s first folding phone was released in 2019, but got off to a rocky start. The initial launch was delayed after reviewers — including CNBC — discovered that the early devices would break along their folding crease.
But Samsung says this time is different, and that folding phones are finally ready to go mainstream, especially with respect to durability.
“There really are no longer trade-offs towards owning a foldable device,” said Drew Blackard, vice president of mobile product management at Samsung Electronics America.
The South Korean company doesn’t provide sales numbers, but Blackard said the Galaxy Z Fold 7, the latest version, had 25% more preorders than any previous Samsung folding phone and that sales are outpacing the device’s predecessor by nearly 50%.
“Samsung with the foldable is able to actually optimize for innovation,” said Bjorhovde. “Try to be ahead, show that something is different, and there’s a certain halo effect from that.”
According to Counterpoint Research, a firm that estimates smartphone sales to customers, Samsung’s sell-through increased 16% during the June quarter, thanks to demand for high-end devices, including a “slight boost” from the slim S25 Edge.
The rise of artificial intelligence is also heralding new form factors for consumer electronics that could one day replace the iPhone.
OpenAI in May acquired the startup of former Apple design guru Jony Ive for $6.5 billion. The AI startup plans to develop the next generation of hardware, and other AI startups have released pins, pendants and glasses that rely on users’ voice to control the devices.
Samsung devices, as well as other Android phones, get access to Google’s Gemini, which is widely considered to be one of the best AI models alongside OpenAI’s ChatGPT. Gemini has several features that users can’t get with Siri and Apple Intelligence.
Blackard said folding phones, with their larger displays, are well suited for AI. Google’s circle-to-search feature, which allows a user to simply circle something on the screen that they’d like to learn more about, is an example, Blackard said.
On a Samsung folding phone, he said, users can still see the original screen with the content they circled, as well as another screen with supplementary information.
“It’s much more productive being able to go back and forth,” Blackard said.
Investors have worried that Apple’s AI delays, including its next-generation Siri that’s now scheduled to come out next year, could start hurting sales. But many analysts say that Apple’s brand loyalty and lock-in will give it a period of years before iPhone customers start defecting for competitors.
Chatterjee told CNBC that Apple’s strategy with devices is to wait until a technology is ready for the mainstream before embracing it. That time may be now for foldable devices.
Apple has “never been about trying to be the first to market,” Chatterjee said. “It’s about being watchful, seeing a technology mature, knowing that there are no big roadblocks to that technology adoption, and then moving ahead.”
Trending
-
Sports3 years ago
‘Storybook stuff’: Inside the night Bryce Harper sent the Phillies to the World Series
-
Sports1 year ago
Story injured on diving stop, exits Red Sox game
-
Sports2 years ago
Game 1 of WS least-watched in recorded history
-
Sports2 years ago
MLB Rank 2023: Ranking baseball’s top 100 players
-
Sports4 years ago
Team Europe easily wins 4th straight Laver Cup
-
Sports2 years ago
Button battles heat exhaustion in NASCAR debut
-
Environment2 years ago
Japan and South Korea have a lot at stake in a free and open South China Sea
-
Environment2 years ago
Game-changing Lectric XPedition launched as affordable electric cargo bike